on Wednesday said it was discontinuing its heart surgery robot business as it posted a 30% drop in second-quarter operating profit on shrinking demand for COVID-19 tests.
The "use of Corindus robots for cardiology operations did not fulfill our expectations," Chief Financial Officer Jochen Schmitz said on a press call. Schmitz added it will take several years before robots for neurological operations are ready for the market.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: Reuters - 🏆 2. / 97 続きを読む »